Published in Cancer on March 01, 2006
YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene (2009) 1.97
Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol (2009) 1.46
Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights (2007) 1.40
Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor α2. Cell Rep (2013) 1.24
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00
Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol (2007) 0.98
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res (2007) 0.92
YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol (2010) 0.91
Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res (2014) 0.89
Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer (2010) 0.88
CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res (2013) 0.88
Evaluating biomarkers in melanoma. Front Oncol (2015) 0.83
YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) (2010) 0.83
Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett (2010) 0.81
Circulating glioma biomarkers. Neuro Oncol (2014) 0.80
Utility of Serum YKL-40 as a Tumor-Specific Marker of Hepatobiliary Malignancies. Gut Liver (2010) 0.80
Adjuvant therapy: melanoma. J Skin Cancer (2011) 0.78
Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One (2014) 0.77
Human cartilage chitinase 3-like protein 2: cloning, expression, and production of polyclonal and monoclonal antibodies for osteoarthritis detection and identification of potential binding partners. Monoclon Antib Immunodiagn Immunother (2013) 0.77
Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer (2011) 0.76
YKL-40 expression in soft-tissue sarcomas and atypical lipomatous tumors. An immunohistochemical study of 49 tumors. Acta Orthop (2014) 0.76
RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Sci Rep (2016) 0.75
Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection. World J Gastrointest Oncol (2016) 0.75
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol (2009) 5.11
Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol (2002) 2.88
Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol (2006) 2.64
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol (2009) 2.13
Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev (2003) 2.08
Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J Clin Oncol (2008) 2.06
Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol (2005) 2.01
Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res (2007) 1.87
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum (2011) 1.71
Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol (2002) 1.61
Plasma YKL-40, a new biomarker for atrial fibrillation? Europace (2009) 1.59
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol (2006) 1.53
Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One (2009) 1.44
Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol (2007) 1.43
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res (2005) 1.34
Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst (2002) 1.34
Management of cutaneous metastases using electrochemotherapy. Acta Oncol (2011) 1.32
Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res (2011) 1.27
Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab (2008) 1.24
Electric pulse-mediated gene delivery to various animal tissues. Adv Genet (2005) 1.21
Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother (2004) 1.12
The value of gynecologic cancer follow-up: evidence-based ignorance? Int J Gynecol Cancer (2010) 1.11
ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis (2011) 1.10
Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res (2006) 1.09
YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J (2008) 1.08
Physiological effects of high- and low-voltage pulse combinations for gene electrotransfer in muscle. Hum Gene Ther (2008) 1.08
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother (2008) 1.07
Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncol (2012) 1.06
Optimizing clinical performance and geometrical robustness of a new electrode device for intracranial tumor electroporation. Bioelectrochemistry (2011) 1.06
Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients. Dis Markers (2008) 1.04
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol (2006) 1.04
Prevalence and risk of depressive symptoms 3-4 months post-surgery in a nationwide cohort study of Danish women treated for early stage breast-cancer. Breast Cancer Res Treat (2008) 1.04
Impact of changes in bladder and rectal filling volume on organ motion and dose distribution of the bladder in radiotherapy for urinary bladder cancer. Int J Radiat Oncol Biol Phys (2004) 1.03
Gene electrotransfer to skin; review of existing literature and clinical perspectives. Curr Gene Ther (2010) 1.03
Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res (2009) 1.02
Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer. Int J Cancer (2002) 1.00
Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res (2012) 1.00
Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol (2003) 0.99
Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol (2012) 0.99
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg (2013) 0.97
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol (2002) 0.96
Gene expression profiles in skeletal muscle after gene electrotransfer. BMC Mol Biol (2007) 0.94
YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology (2010) 0.94
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy (2010) 0.93
Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum Gene Ther Clin Dev (2013) 0.92
What you always needed to know about electroporation based DNA vaccines. Hum Vaccin Immunother (2012) 0.92
Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol (2010) 0.92
Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc (2009) 0.90
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer (2005) 0.90
Tet-On induction with doxycycline after gene transfer in mice: sweetening of drinking water is not a good idea. Anim Biotechnol (2007) 0.90
Health-related quality of life in long-term survivors of testicular cancer. J Clin Oncol (2009) 0.89
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res (2012) 0.89
Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy. Radiol Oncol (2013) 0.89
Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res (2005) 0.88
Bleomycin treatment of brain tumors: an evaluation. Anticancer Drugs (2009) 0.88
Electroporation enhances mitomycin C cytotoxicity on T24 bladder cancer cell line: a potential improvement of intravesical chemotherapy in bladder cancer. Bioelectrochemistry (2012) 0.88
Diffusion-weighted MRI for verification of electroporation-based treatments. J Membr Biol (2011) 0.88
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med (2013) 0.85
Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res (2010) 0.85
A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma. Radiother Oncol (2005) 0.84
Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther (2006) 0.84
Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol (2004) 0.84
Efficacy of transgene expression in porcine skin as a function of electrode choice. Bioelectrochemistry (2011) 0.83
Efficiency of cellular delivery of antisense peptide nucleic acid by electroporation depends on charge and electroporation geometry. Oligonucleotides (2011) 0.83
Predicting patients at risk for pain associated with electrochemotherapy. Acta Oncol (2015) 0.82
Immunohistochemical study of the expression of cell cycle regulating proteins at different stages of bladder cancer. J Cancer Res Clin Oncol (2002) 0.81
Amplification of epidermal growth factor receptor gene in renal cell carcinoma. Eur J Cancer (2010) 0.81
Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol (2002) 0.80
Change in Hemoglobin Levels due to Anesthesia in Mice: An Important Confounder in Studies on Hematopoietic Drugs. Biol Proced Online (2009) 0.80
Fear of recurrence and causal attributions in long-term survivors of testicular cancer. Psychooncology (2011) 0.79
Spatial distribution of transgenic protein after gene electrotransfer to porcine muscle. Hum Gene Ther Methods (2013) 0.79
Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol (2006) 0.79
Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil? J Clin Oncol (2005) 0.79
Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack. Clin Cancer Res (2004) 0.79
Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients. Cancer Immunol Immunother (2004) 0.78
Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiother Oncol (2004) 0.78
Screening for Y microdeletions in men with testicular cancer and undescended testis. J Assist Reprod Genet (2006) 0.78
Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int (2008) 0.77
The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma. J Immunother (2007) 0.77
In Vivo Imaging of Far-red Fluorescent Proteins after DNA Electrotransfer to Muscle Tissue. Biol Proced Online (2009) 0.77
Calcium electrotransfer for termination of transgene expression in muscle. Hum Gene Ther (2011) 0.77
Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast Cancer Res Treat (2011) 0.76
Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Biomark Insights (2009) 0.76